Boehringer Sued Over $120M Pay-For-Delay On Stroke Drug

Law360, Los Angeles (November 12, 2013, 8:27 PM EST) -- Miami-Luken Inc., a wholesaler to pharmacies, accused Boehringer Ingelheim Pharmaceuticals Inc. of orchestrating a $120 million pay-for-delay deal to keep generic versions of its stroke prevention medication off the market, according to a putative class action filed in Pennsylvania federal court Friday.

Miami-Luken says it has been buying Boehringer’s Aggrenox at artificially inflated prices because Boehringer paid off a potential competitor in 2008, agreeing to give it a share of Aggrenox’s profits in exchange for delaying sale of the generic for seven years.

Miami-Luken alleges that...
To view the full article, register now.